Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Aethlon Medical Stock Up 3.2 %

AEMD stock opened at $1.46 on Friday. The firm has a market cap of $3.83 million, a PE ratio of -0.29 and a beta of 1.88. The business has a 50 day moving average of $1.66 and a 200-day moving average of $1.77. Aethlon Medical has a 12-month low of $1.35 and a 12-month high of $7.20.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.14). On average, research analysts expect that Aethlon Medical will post -4.98 earnings per share for the current year.

Institutional Investors Weigh In On Aethlon Medical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock valued at $613,000 after buying an additional 558,596 shares during the period. Jane Street Group LLC raised its holdings in shares of Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 126,160 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Aethlon Medical during the 3rd quarter valued at about $72,000. HRT Financial LP purchased a new position in shares of Aethlon Medical during the fourth quarter worth about $28,000. Finally, Two Sigma Investments LP increased its position in shares of Aethlon Medical by 219.3% in the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 87,458 shares during the last quarter. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.